Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Jay P. Patel, Mithat Gönen, Ph.D., Maria E. Figueroa, M.D., Hugo Fernandez, M.D., Zhuoxin Sun, Ph.D., Janis Racevskis, Ph.D., Pieter Van Vlierberghe, Ph.D., Igor Dolgalev, B.S., Sabrena Thomas, B.S., Olga Aminova, B.S., Kety Huberman, B.S., Janice Cheng, B.S., Agnes Viale, Ph.D., Nicholas D. Socci, Ph.D., Adriana Heguy, Ph.D., Athena Cherry, Ph.D., Gail Vance, M.D., Rodney R. Higgins, Ph.D., Rhett P. Ketterling, M.D., Robert E. Gallagher, M.D., Mark Litzow, M.D., Marcel R.M. van den Brink, M.D., Ph.D., Hillard M. Lazarus, M.D., Jacob M. Rowe, M.D., Selina Luger, M.D., Adolfo Ferrando, M.D., Ph.D., Elisabeth Paietta, Ph.D., Martin S. Tallman, M.D., Ari Melnick, M.D., Omar Abdel-Wahab, M.D., and Ross L. Levine, M.D.

The authors’ affiliations are listed in the Appendix. Address reprint requests to Dr. Levine at the Human Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 20, New York, NY 10065, or at leviner@mskcc.org.

Mr. Patel and Drs. Gonen, Abdel-Wahab, and Levine contributed equally to this article.

This article (10.1056/NEJMoa1112304) was published on March 14, 2012, at NEJM.org.


Copyright © 2012 Massachusetts Medical Society.

ABSTRACT

BACKGROUND

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for AML.

METHODS

We performed a mutational analysis of 18 genes in 398 patients younger than 60 years of age who had AML and who were randomly assigned to receive induction therapy with high-dose or standard-dose daunorubicin. We validated our prognostic findings in an independent set of 104 patients.

RESULTS

We identified at least one somatic alteration in 97.3% of the patients. We found that internal tandem duplication in FLT3 (FLT3-ITD), partial tandem duplication in MLL (MLL-PTD), and mutations in ASXL1 and PHF6 were associated with reduced overall survival (P=0.001 for FLT3-ITD, P=0.009 for MLL-PTD, P=0.05 for ASXL1, and P=0.006 for PHF6); CEBPA and IDH2 mutations were associated with improved overall survival (P=0.05 for CEBPA and P=0.01 for IDH2). The favorable effect of NPM1 mutations was restricted to patients with co-occurring NPM1 and IDH1 or IDH2 mutations. We identified genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, and validated the significance of these predictors in an independent cohort. High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67).

CONCLUSIONS

We found that DNMT3A and NPM1 mutations and MLL translocations predicted an improved outcome with high-dose induction chemotherapy in patients with AML. These findings suggest that mutational profiling could potentially be used for risk stratification and to inform prognostic and therapeutic decisions regarding patients with AML. (Funded by the National Cancer Institute and others.)
Preva

Previous studies have highlighted the clinical and biologic heterogeneity of acute myeloid leukemia (AML). However, a relatively small number of cytogenetic and molecular lesions have sufficient relevance to influence clinical practice. The prognostic relevance of cytogenetic abnormalities has led to the widespread adoption of risk stratification, with patients divided into three cytogenetically defined risk groups with significant differences in overall survival. More recently, FLT3, NPM1, and CEBPA mutational analysis was shown to improve risk stratification for patients who do not have karyotypic abnormalities. Although progress has been made in defining prognostic markers for AML, a substantial percentage of patients lack a specific abnormality of prognostic significance. In addition, there is considerable heterogeneity in the outcome for individual patients in each risk group.

Recent studies have identified novel recurrent somatic mutations in patients with AML. These include mutations in TET2, ASXL1, IDH1 or IDH2, DNMT3A, PHF6, and RUNX1. Retrospective analyses suggest that a subset of these mutations may have prognostic significance in AML, although these findings have not been validated with detailed clinical and mutational annotation in large, homogeneously treated cohorts of patients with AML. In addition, the question of whether mutational profiling of a larger set of genes, including these novel disease alleles, improves prognostication in AML has not been investigated in a clinical trial cohort.

A recent phase 3 clinical trial (E1900; Clinical Trials.gov number, NCT00049517) from the Eastern Cooperative Oncology Group (ECOG) showed that induction therapy with cytarabine plus 90 mg of daunorubicin per square meter of body-surface area, as compared with cytarabine plus 45 mg of daunorubicin per square meter, improved the outcomes in patients with newly diagnosed AML who were 17 to 60 years of age; a similar study in patients who were older than 60 years of age showed that dose-intensified daunorubicin improved overall survival in patients 60 to 65 years of age. We hypothesized that integrated mutational analysis of all known molecular alterations occurring in more than 5% of patients with AML would allow us to identify novel molecular markers of outcome in AML and to identify molecularly defined subgroups of patients who would benefit from dose-intensified induction chemotherapy.

Methods

Patients

We performed mutational analysis on diagnostic samples obtained from patients in the ECOG E1900 trial. All patients provided written informed consent. The test cohort (398 patients) comprised all patients in the E1900 trial for whom viably frozen cells were available for DNA extraction and mutational profiling. The validation cohort (104 patients) comprised a second set of patients for whom samples were banked in Trizol reagent (Invitrogen), which was used to extract DNA for mutational studies. The clinical characteristics of the patients we studied, as compared with the complete E1900 trial cohort, are provided in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org. The median follow-up time for the patients included in the analysis, calculated from the time of randomization for induction therapy, was 47.4 months. Cytogenetic analysis, fluorescence in situ hybridization, and reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays for recurrent cytogenetic lesions were performed as described initially by Slovak et al. and as used previously, with central review by the ECOG Cytogenetic Subcommittee.

Mutational Analysis

The source of the DNA was bone marrow in the case of 55.2% of the samples (277 of 502) and peripheral blood in the case of 44.8% (225 of 502). We sequenced the entire coding regions of TET2, ASXL1, DNMT3A, CEBPA, PHF6, WT1, TP53, EZH2, RUNX1, and PTEN and the regions of previously described mutations for FLT3, NPM1, HRAS, KRAS, NRAS, KIT, IDH1, and IDH2. The genomic coordinates and sequences of all the primers used in this study are provided in Table S2 in the Supplementary Appendix. Paired remission DNA (i.e., DNA from patients who had a complete remission after induction chemotherapy) was available from 241 of the 398 participants in the test cohort and from 65 of the 104 in the validation cohort. Data on variants that could not be validated as bona fide somatic mutations owing to unavailable remission DNA and the absence of reports of the mutations in the published literature of somatic mutations were censored with respect to mutational status for that specific gene. Further details of the sequencing methods are available in the Supplementary Appendix.
The New England Journal of Medicine

The mutual exclusivity of pairs of mutations was evaluated with the use of two-by-two contingency tables and Fisher’s exact test. The association between mutations and cytogenetic risk classification was tested with the use of the chi-square test. Hierarchical clustering was performed with the use of the Lance-Williams dissimilarity formula and the complete-linkage algorithm. Survival time was measured from the date of randomization to the date of death for patients who died and to the date of the last follow-up for those who were alive at the time of the analysis. Survival probabilities were estimated with the use of the Kaplan–Meier method and were compared between patients with a mutation and those without mutant alleles by means of the log-rank test. Multivariate analyses were conducted with the use of the Cox model with forward selection. We checked the proportional-hazards assumption by testing for a nonzero slope in a regression of the scaled Schoenfeld residuals on functions of time (Table S3 in the Supplementary Appendix). When necessary, such as in the analyses performed in various subsets, the results of the univariate analyses were used to select the variables to be included in the forward variable search. Final multivariate models informed the development of novel risk-classification rules. When so indicated, P values were adjusted to control the family-wise error rate with the use of the complete null distribution approximated by resampling obtained through the PROC MULTITEST program in SAS or the multitest library in R.\(^{19}\) The only exception was the adjustment in tests of the effect of mutations on the response to the induction dose, for which a step-down Holm procedure was used to control for multiple testing. All analyses were performed with the use of SAS software, version 9.2 (www.sas.com), and the R statistical package, version 2.12 (www.r-project.org).

**STATISTICAL ANALYSIS**

**RESULTS**

**FREQUENCY OF GENETIC ALTERATIONS**

Somatic alterations were identified in 97.3% of the patients. Figure 1 shows the frequency of somatic mutations in the entire cohort and the interrelationships among the various mutations, as represented visually with the use of a Circos plot. Data for all molecular subsets are provided in Figures S1 and S2 and Tables S4 and S5 in the Supplementary Appendix. In particular, mutation-specific heterogeneity was greater in patients with intermediate-risk AML than in patients with favorable-risk or unfavorable-risk risk AML (P=0.01) (Fig. S2D in the Supplementary Appendix).

**MUTATIONAL COMPLEMENTATION GROUPS**

Integrated mutational analysis allowed us to identify frequently co-occurring mutations and mutations that were mutually exclusive in the E1900 patient cohort (Table S6 in the Supplementary Appendix). In addition to noting frequent co-occurrence of \(K\)IT mutations with core-binding–factor alterations t(8;21) and inv(16)/t(16;16), we found significant co-occurrence of \(ID\)H1 and \(ID\)H2 mutations with \(NPM1\) mutations and of \(DNMT3A\) mutations with \(NPM1\), \(FL3\), and \(ID\)H1 alleles (P<0.001 for all comparisons) (Table S7 in the Supplementary Appendix). We recently reported that \(ID\)H1 and \(ID\)H2 mutations were mutually exclusive with \(TET2\) mutations\(^{20}\); detailed mutational analysis revealed that \(ID\)H1 and \(ID\)H2 mutations were also mutually exclusive with \(WT\)1 mutations (P<0.001) (Fig. S3 and Table S8 in the Supplementary Appendix). We also observed that \(DNMT3A\) mutations and \(MLL\) translocations were mutually exclusive (P<0.01).

**MOLECULAR DETERMINANTS OF OVERALL SURVIVAL**

Univariate analysis revealed, as previously described,\(^{21,22}\) that \(FL3\) internal tandem duplication (\(FL3\)-ITD) mutations and \(MLL\) partial tandem duplication (\(MLL\)-PTD) mutations were associated with reduced overall survival (P=0.001 for \(FL3\)-ITD and P=0.009 for \(MLL\)-PTD) (Table S9 in the Supplementary Appendix), whereas \(CEBPA\) mutations and core-binding–factor alterations t(8;21) and inv(16)/t(16;16) were associated with improved overall survival (P=0.05 for \(CEBPA\) and P<0.001 for the core-binding–factor alterations).\(^{2,23}\) In addition, \(PHF6\) and \(ASXL1\) mutations were associated with reduced overall survival (P=0.006 for \(PHF6\) and P=0.05 for \(ASXL1\)) (Fig. S4 in the Supplementary Appendix). \(ID\)H2 mutations were associated with an improved rate of overall survival in the entire test cohort (3-year rate, 66%; P=0.01) (Fig. S5 in the Supplementary Appendix). The favorable effect of \(ID\)H2 mutations was found exclusively in patients with \(ID\)H2 R140Q mutations (P=0.009) (Fig. S5 in the Supplementary Appendix). All the findings in the univariate analysis were also significant in the multivariate analysis (P<0.05, with adjustment for age, white-cell count, transplantation status [did vs. did not...
undergo stem-cell transplantation], and cytogenetic characteristics) (Table S9 in the Supplementary Appendix), with the exception of the findings for MLL-PTD, PHF6, and ASXL1 mutations.

KIT mutations were associated with reduced overall survival among patients who were positive for the t(8;21) core-binding–factor alteration (P=0.006) but not among patients with the

---

**Table 1. Mutational Frequency in AML**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Overall Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLT3 (ITD, TKD)</td>
<td>37 (30, 7)</td>
</tr>
<tr>
<td>NPM1</td>
<td>29</td>
</tr>
<tr>
<td>DNMT3A</td>
<td>23</td>
</tr>
<tr>
<td>NRAS</td>
<td>10</td>
</tr>
<tr>
<td>CEBPA</td>
<td>9</td>
</tr>
<tr>
<td>TET2</td>
<td>8</td>
</tr>
<tr>
<td>WT1</td>
<td>8</td>
</tr>
<tr>
<td>IDH2</td>
<td>8</td>
</tr>
<tr>
<td>IDH1</td>
<td>7</td>
</tr>
<tr>
<td>KIT</td>
<td>6</td>
</tr>
<tr>
<td>RUNX1</td>
<td>5</td>
</tr>
<tr>
<td>MLL-PTD</td>
<td>5</td>
</tr>
<tr>
<td>ASXL1</td>
<td>3</td>
</tr>
<tr>
<td>PHF6</td>
<td>3</td>
</tr>
<tr>
<td>KRAS</td>
<td>2</td>
</tr>
<tr>
<td>PTEN</td>
<td>2</td>
</tr>
<tr>
<td>TP53</td>
<td>2</td>
</tr>
<tr>
<td>HRAS</td>
<td>0</td>
</tr>
<tr>
<td>EZH2</td>
<td>0</td>
</tr>
</tbody>
</table>

**Figure 1. Mutational Complexity of Acute Myeloid Leukemia (AML).**

A Circos diagram (Panel A) depicts the relative frequency and pairwise co-occurrence of mutations in patients with newly diagnosed AML who were enrolled in the Eastern Cooperative Oncology Group E1900 clinical trial. The length of the arc corresponds to the frequency of mutations in the first gene, and the width of the ribbon corresponds to the percentage of patients who also had a mutation in the second gene. Pairwise co-occurrence of mutations is denoted only once, beginning with the first gene in the clockwise direction. Panel A also shows the frequency of mutations in the test cohort. Panels B and C show the mutational events in patients with mutant DNMT3A and mutant FLT3, respectively. Since, for clarity, only pairwise mutations are encoded, the arc length was adjusted to maintain the relative size of the arc, and the correct proportion of patients with only a single mutant allele is represented by the not-otherwise-occupied space within each mutational subset (all panels). ITD denotes internal tandem duplication, PTD partial tandem duplication, and TKD tyrosine kinase domain.
inv(16)/t(16;16) alteration (P = 0.19) (Fig. S6 in the Supplementary Appendix).

PROGNOSTIC VALUE OF MOLECULAR ALTERATIONS IN INTERMEDIATE-RISK AML

Among patients with intermediate-risk AML as defined by cytogenetic analysis (Table S10 in the Supplementary Appendix), FLT3-ITD mutations were associated with reduced overall survival (P = 0.008), a finding that was consistent with the results of previous studies.\(^1\) ASXL1 and PHF6 mutations were associated with reduced survival, and IDH2 R140Q mutations with improved survival, among patients with intermediate-risk AML (Table S10 in the Supplementary Appendix), an effect similar to that in the entire cohort. In addition, we found that TET2 mutations were associated with reduced overall survival among patients with intermediate-risk AML (P = 0.007) (Fig. S7 in the Supplementary Appendix).

Multivariate analysis revealed that FLT3-ITD mutations constituted the primary predictor of outcome in patients with intermediate-risk AML (adjusted P < 0.001). A subsequent multivariate analysis according to FLT3-ITD status showed that in patients with wild-type FLT3-ITD, mutations in TET2, ASXL1, PHF6, and MLL-PTD were independently associated with an adverse outcome. Patients with intermediate-risk AML who had both NPM1 and IDH1 or IDH2 mutations had an improved 3-year rate of overall survival, as compared with patients who had mutant NPM1 and both wild-type IDH1 and wild-type IDH2 (89% vs. 31%, P < 0.001) (Fig. S8 in the Supplementary Appendix). We then classified patients with intermediate-risk AML who had wild-type FLT3-ITD into three categories, with marked differences in the 3-year rate of overall survival (adjusted P < 0.001): patients with IDH1 or IDH2 mutations and NPM1 mutations (overall survival, 89%); patients with TET2, ASXL1, PHF6, or MLL-PTD mutations (overall survival, 6.3%); and patients with wild-type TET2, ASXL1, PHF6, and MLL-PTD, without co-occurring IDH or NPM1 mutations (overall survival, 46.2%) (Fig. 2A). Similar results were obtained when the analysis was restricted to patients with a normal karyotype (Fig. S9A in the Supplementary Appendix).

In patients with intermediate-risk AML who had mutant FLT3-ITD, we found that CEBPA mutations were associated with an improved outcome and that trisomy 8 and TET2, DNMT3A, and MLL-PTD mutations were associated with an adverse outcome. We used these data to classify patients with intermediate-risk AML who had mutant FLT3-ITD into three categories. The first category included patients with trisomy 8 or TET2, DNMT3A, or MLL-PTD mutations, which were associated with an adverse outcome (3-year rate of overall survival, 14.5%); this rate of survival was significantly lower than the rates among patients in the second category, those with wild-type CEBPA, TET2, DNMT3A, and MLL-PTD (overall survival, 35.2%; P < 0.001), and patients in the third category, those with CEBPA mutations (overall survival, 42%; P < 0.001) (Fig. 2B). The rate of survival among patients with intermediate-risk AML who had mutant FLT3-ITD and wild-type CEBPA, TET2, DNMT3A, and MLL-PTD did not differ significantly from the rate among patients with mutant FLT3-ITD and mutant CEBPA (P = 0.34), suggesting that the presence of mutations associated with an unfavorable-risk profile more precisely identifies patients with mutant FLT3-ITD who will have adverse outcomes of AML than does the absence of CEBPA mutations alone. These three risk categories also had significant prognostic value in patients with AML who had mutant FLT3-ITD and a normal karyotype (Fig. S9B in the Supplementary Appendix).

PROGNOSTIC SCHEMA WITH INTEGRATED MUTATIONAL AND CYTOGENETIC PROFILING

These results allowed us to develop a prognostic schema that integrated our findings from the comprehensive mutational analysis with cytogenetic data to identify three risk groups: a group with a favorable-risk profile (median survival, not reached; 3-year rate of overall survival, 64%), a group with an intermediate-risk profile (median survival, 25.4 months; 3-year rate of overall survival, 42%), and a group with an adverse-risk profile (median survival, 10.1 months; 3-year rate of overall survival, 12%) (Fig. 3A and 3B, and Table S11 in the Supplementary Appendix). In multivariate analysis, the mutational prognostic schema predicted the outcome independently of age, white-cell count, induction dose, and transplantation status (adjusted P < 0.001). Our classification held true regardless of the type of postremission therapy (autologous or allogeneic transplantation or consolidation chemotherapy alone) (Fig. S10 in the Supplementary Appendix). Given the number of variables in our prognostic classification, we tested the reproducibil-
ity of this predictor in an independent cohort of 104 patients from the ECOG E1900 trial. Mutational analysis of the validation cohort confirmed the reproducibility of our prognostic schema for predicting the outcome in patients with AML (adjusted P<0.001) (Fig. 3C). The predictive value of the mutational prognostic schema was independent of risk with respect to treatment-related death (defined as death within 30 days after initiation of treatment) or lack of response to induction chemotherapy (i.e., lack of a complete remission) in the test cohort and in the combined test and validation cohorts (Table S12 in the Supplementary Appendix).

**Genetic Predictors of Response to Induction Chemotherapy**

Recent studies have shown that mutant DNMT3A was associated with adverse outcomes in patients with AML. However, we found that DNMT3A mutations were not associated with adverse outcomes in the ECOG E1900 cohort (Fig. 4A) (P=0.15). In the ECOG E1900 trial, patients were randomly assigned to induction therapy with cytarabine plus either 45 mg of daunorubicin per square meter or 90 mg of daunorubicin per square meter. We therefore hypothesized that high-dose daunorubicin improved the outcomes in patients with daunorubicin who had DNMT3A mutations. Indeed, we found that DNMT3A mutational status had a significant effect on the outcome with dose-intensive chemotherapy (Fig. 4B) (P=0.02). We then assessed the effects of DNMT3A mutational status on the outcome according to treatment group and found that high-dose daunorubicin was associated with an improved rate of survival among patients with mutant DNMT3A (P=0.04) (Fig. S11A in the Supplementary Appendix) but not among patients with wild-type DNMT3A (P=0.15) (Fig. S11B in the Supplementary Appendix). In addition, univariate analysis revealed that dose-intensified induction therapy was associated with an improved outcome in patients...
with AML who had MLL translocations (P = 0.01; P = 0.06 with adjustment for multiple testing) (Fig. S11C and S11D in the Supplementary Appendix) and in those who had NPM1 mutations (P = 0.01; P = 0.10 with adjustment for multiple testing) (Fig. S11E and S11F and Table S13 in the Supplementary Appendix). Because the adjusted P values for NPM1 mutations and MLL translocations (P ≤ 0.10) are close to statistical significance, they should be studied further in prospective trials.

We then separated the patients in our cohort into two groups: patients with mutations in DNMT3A or NPM1 or with MLL translocations and patients with wild-type DNMT3A and NPM1 and no MLL translocations. Dose-intensive induction therapy was associated with a marked improvement in the rate of survival among patients who were positive for DNMT3A or NPM1 mutations or MLL translocations (P = 0.001) (Fig. 4C) but not among patients with wild-type DNMT3A and NPM1 and no MLL translocations (P = 0.67) (Fig. 4D). This finding was independent of the clinical covariates of age, white-cell count, and status with respect to transplantation, treatment-related death, and response to chemotherapy (adjusted P = 0.008 and P = 0.34 for patients with mutant and wild-type genes, respectively), suggesting that high-dose anthracycline chemotherapy provides a benefit in genetically defined subgroups of patients with AML.

**COMPREHENSIVE MUTATIONAL PROFILING FOR RISK STRATIFICATION AND CLINICAL MANAGEMENT OF AML**

On the basis of cytogenetic classification alone, 63% of the patients in the ECOG E1900 cohort were categorized as having an intermediate-risk
AML profile (3-year rate of overall survival, 36%), whereas 19% of the patients were classified as having a favorable-risk profile (3-year rate of overall survival, 58%) and 18% as having an unfavorable-risk profile (3-year rate of overall survival, 11%) (Fig. 5A). Mutational analysis allowed for the separation of patients with cytogenetically defined intermediate-risk AML into three subgroups with markedly different outcomes: a subgroup of patients with a favorable mutational risk profile (3-year rate of overall survival, 85%), a subgroup of patients with an unfavorable mutational risk profile (3-year rate of overall survival, 11%) (Fig. 5B).
We describe the frequency of various mutations and the prognostic usefulness and therapeutic relevance of integrated mutational profiling in 398 patients from the ECOG E1900 phase 3 clinical trial and the validation of these data in an independent cohort of 104 patients from the same trial. Previous studies have suggested that mutational analysis of CEBPA, NPM1, and FLT3-ITD can be used to stratify risk among patients with intermediate-risk AML. Using data from a large cohort of patients treated in a single clinical trial, we found that more extensive mutational analysis can better discriminate patients with AML into various prognostic groups (Fig. 3). For example, patients without FLT3-ITD mutations and with both mutant NPM1 and IDH represent a favorable-risk subset defined by a specific mutational genotype, whereas patients who were negative for FLT3-ITD mutations and had mutant NPM1 without concurrent IDH mutations had a much less favorable outcome — particularly if those patients had concurrent mutations associated with an unfavorable-risk profile. We also found that TET2, ASXL1, MLL-PTD, PHF6, and DNMT3A mutations can identify patients with intermediate-risk AML who will have an adverse outcome. Taken together, these data show that mutational analysis of a larger set of genetic alterations than that currently used in the clinic setting could be used to retrospectively classify patients with AML into more precise subgroups with favorable-risk, intermediate-risk, or unfavorable-risk profiles, with marked differences in the overall outcome. This approach could be used to identify an additional subgroup of patients who would have a mutationally defined favorable outcome with induction and consolidation therapy alone and a subgroup of patients with mutationally defined unfavorable risk who would potentially be candidates for allogeneic stem-cell transplantation or participation in a clinical trial, given the prediction of a poor outcome with standard AML therapy (Fig. 5A).

The two recent randomized trials examining the benefits of intensification of the dose of anthracycline in patients with AML showed that more intensive induction chemotherapy improved the outcomes. An evaluation of the data from the overall cohort in the E1900 trial showed that the distribution of patients among
genetic risk categories in both treatment groups was similar to the distribution in our cohort of 502 patients (P = 0.41 by Pearson’s chi-square test). However, the initial reports of the two recent trials did not identify whether dose-intensified induction therapy improved the outcomes in various AML subgroups. We found that intensification of the dose of anthracycline markedly improved the outcomes in patients with mutations in DNMT3A or NPM1 or with MLL translocations, suggesting that mutational profiling can be used to determine which patients will benefit from dose-intensive induction therapy (Fig. 5B). Future studies will be needed to determine whether there are additional subgroups of patients with AML who will benefit from dose-intensified induction therapy and whether dose-intensified induction therapy improves the outcome in patients with AML who are older than 60 years of age and have mutations in DNMT3A or NPM1 or MLL translocations.

We also identified mutational combinations that occur commonly in patients with AML and those that rarely, if ever, co-occur; these findings are consistent with the existence of additional mutational complementation groups with gene mutations that are mutually exclusive with one another in large patient cohorts. For example, the observation that TET2 and IDH mutations were mutually exclusive in this AML cohort led to functional studies linking IDH mutations and loss-of-function TET2 mutations in a shared mechanism of hematopoietic transformation.20

The data in this study show a way in which integrated mutational profiling of a clinical trial cohort can advance our understanding of the biologic characteristics of AML, improve current prognostic models, and inform therapeutic decisions. Most important, these data indicate that more detailed genetic analysis may lead to improved risk stratification and identification of patients who can benefit from more intensive induction chemotherapy. The challenge is to provide genetic information in a timely and affordable way and show that this information could prospectively influence treatment decisions.

Supported by grants from the National Cancer Institute (NCI) Physical Sciences Oncology Center (US5CA143798-01, to Dr. Levine), the Gabrielle’s Angel Fund (to Dr. Levine), and the Starr Cancer Consortium (to Drs. Levine and Melnick) and funding from the Peter Solomon Fund at Memorial Sloan-Kettering Cancer Center. Mr. Patel is supported by an American Society of Hematology Trainee Research Award; Dr. Figueroa is funded by a Leukemia and Lymphoma Society Special Fellow Award; Drs. Van Vlierbergh and Abdel-Wahab are American Society of Hematology Basic Research Fellows; Dr. Vannierbergh is supported by the Fund for Scientific Research (FWO) Flanders; Dr. Melnick is funded by a Leukemia and Lymphoma Society Specialized Center of Research Award and Translational Research Program Award and is a Burroughs Wellcome Clinical Translational Scholar and a Scholar of the Leukemia and Lymphoma Society; Drs. Figueroa and Melnick are also supported by the Sackler Center for Biomedical and Physical Sciences; Dr. Levine is the recipient of an Early Career Award from the Howard Hughes Medical Institute; Dr. Paita is supported by NCI grants CA21115 and CA114737; Dr. Gallagher is supported by NCI grant CA56771; and Dr. Ferrando is funded by a Leukemia and Lymphoma Society Scholar Award.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Martin Carroll, Charles Sawyers, Craig Thompson, and Stephen Nimer for their insight and suggestions.

APPENDIX

The authors’ affiliations are as follows: the Human Oncology and Pathogenesis Program (J.P.P., I.D., S.T., O.A., K.H., A.H., O.A.-W., R.L.L.), the Departments of Epidemiology and Biostatistics (M.G.) and Medicine (M.R., M.B.), the Genomics Core Laboratory (J.C., A.V.), the Bioinformatics Core (N.D.S.), and the Leukemia Service, Department of Medicine (M.S.T., O.A.-W., R.L.L.), Memorial Sloan-Kettering Cancer Center, the Department of Medicine, Hematology/Oncology Division, Weill Cornell Medical College (M.E.F., A.M.), Montefiore Medical Center (J.R., R.E.G., E.P.), the Institute for Cancer Genetics and the Departments of Pediatrics and Pathology, Columbia University (P.V.V., A.F.), and the Immunology Program, Sloan-Kettering Institute (M.R.M.B.) — all in New York; the Department of Blood and Bone Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL (H.F.); the Department of Biostatistics, Dana–Farber Cancer Institute, Boston (Z.S.); the Department of Pathology, Stanford Hospital and Clinics, Palo Alto, CA (A.C.); the Department of Medical and Molecular Genetics, Indiana University School of Medicine, Bloomington (G.V.); Allina Cytogentic Laboratory, Abbott Northwestern Hospital, Minneapolis (R.R.H.); the Departments of Laboratory Medicine and Pathology (R.P.K.) and Hematology and Oncology (M.L.), Mayo Clinic College of Medicine, Rochester, MN; the Division of Hematology–Oncology, Case Western Reserve University School of Medicine, Cleveland (H.M.L.); Shaare Zedek Medical Center and Technion, Israel Institute of Technology, Jerusalem (J.M.R.); and the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia (S.L.).

REFERENCES

4. Ley TJ, Ding L, Walter MJ, et al. DNMT3A

Copyright © 2010 Massachusetts Medical Society.